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Introduction: Carbon ion radiotherapy (CIRT) is a promising
modality with excellent localization and significant biologic effects
on tumors. Nevertheless, success depends primarily on accurate
staging before radiotherapy. Surgical interventions should be
avoided in patients considered for CIRT because they usually have
multiple comorbidities. The aim of this study was to evaluate the
effectiveness of endobronchial ultrasound-guided transbronchial
needle aspiration (EBUS-TBNA) for lymph node staging in patients
with non-small cell lung cancer before CIRT.
Methods: From April 2005 to December 2007, 49 patients with
non-small cell lung cancer considered for CIRT with abnormal
positron emission tomography-computed tomography (PET-CT) ac-
cumulations in the mediastinum and/or hilum were evaluated by
EBUS-TBNA. The convex probe EBUS was used for EBUS-TBNA.
Results: There were 38 men and 11 women. Their mean age was
75.2 years (range: 55–87). Based on PET-CT, clinical staging was
four with N1 disease, 42 with N2 disease, and three with N3 disease.
By histology, 26 patients had adenocarcinoma, 19 had squamous
cell carcinoma, and four had other histologies. All positive lymph
nodes on PET-CT were aspirated (range: 1–5; average 2.55 lymph
nodes/patient). EBUS-TBNA diagnosed 43 cases as N0 disease and
as a result underwent CIRT. Forty of the 43 cases remained in stable
condition without local recurrences (follow-up 6–46 months). The
diagnostic accuracy of EBUS-TBNA for lymph node staging was
93.9%.
Conclusions: EBUS-TBNA offers accurate minimally invasive
lymph node staging in patients who are candidates for CIRT.
EBUS-TBNA can be safely performed with a high diagnostic
accuracy before CIRT.
Key Words: Endobronchial ultrasound-guided transbronchial nee-
dle aspiration, Lymph node staging, Carbon ion radiotherapy.
(J Thorac Oncol. 2010;5: 606–611)
Lung cancer is the leading cause of death for men and rankssecond for women in Japan. In 2002, 73,635 new lung
cancer cases were diagnosed, and 46,566 were older than 70
years.1 This is a situation similar to the United States, where
more than 90,000 patients died of lung cancer and more than
20% of them were older than 80 years.2 A less invasive but
effective treatment is required for patients with lung cancer of
advanced age, diminished pulmonary functions, and chronic
diseases, such as cardiovascular disorders. Carbon ion radio-
therapy (CIRT) has been used for inoperable patients with
stage I lung cancer since 1994 in the National Institute of
Radiologic Science (NIRS) in Chiba. From previous reports
for CIRT by the NIRS, we have achieved high local control
with low complication rates.3–5 In contrast to standard ste-
reotactic radiotherapy (SRT) and proton beam radiotherapy,
which show good local control rate in T1 tumors, CIRT has
been shown to be effective even in T2 tumors with a local
control rate of more than 85%.6–10 CIRT is a promising
modality for stage I lung cancer as an alternative to surgical
resection.11
Accurate mediastinal and hilar lymph node staging is
one of the most important factors that determine the outcome
and indications for CIRT. Positive findings in mediastinal or
hilar lymph nodes on positron emission tomography-com-
puted tomography (PET-CT) before CIRT should be con-
firmed by invasive staging. Surgical interventions such as
mediastinoscopy12,13 should be avoided in potential CIRT
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candidates, because they are usually high-risk patients with
multiple comorbidities. Moreover, hilar lymph nodes cannot
be assessed by mediastinoscopy. Endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA) is a
novel, minimally invasive modality that enables the assess-
ment of mediastinal and hilar lymph nodes with a high
sensitivity.14–19
In this study, we evaluated the utility of EBUS-TBNA
for lymph node staging in patients with non-small cell lung
cancer (NSCLC) who are potential candidates for CIRT.
PATIENTS AND METHODS
Patients
All patients referred to CIRT were initially diagnosed
and staged at the referring hospital and also evaluated for
operability. Patients referred to CIRT were all judged as
inoperable or the patients refused surgical resection. Potential
candidates for CIRT underwent a full evaluation at the
Research Center Hospital for Charged Particle Therapy
(NIRS). The indication for CIRT was based on histologic
evidence for the peripheral type of stage I NSCLC. All
patients had a performance status score between 0 and 2
according to the World Health Organization guidelines. Pa-
tients had to have no history of prior radiotherapy to the target
or chemotherapy within 4 weeks before CIRT. For staging,
patients were evaluated by 11C-methionine-PET-CT that was
routinely used for confirmation of metastases. The 11C-me-
thionine accumulation of lymph nodes was assessed semi-
quantitatively by analysis of the tumor-to-muscle ratio
(TMR). The tumor-to-muscle ratio cutoff value for diagnosis
of metastasis was determined as 4.1 following the previous
results.20 If there were abnormal accumulations in mediasti-
nal and/or hilar lymph nodes, further investigation was re-
quired for final confirmation. From April 2005 to December
2007, 49 patients with abnormal 11C-methionine-PET-CT
accumulations in the mediastinum and/or hilum were evalu-
ated by EBUS-TBNA before CIRT. Lymph node stations and
numbers were determined according to the Unio Internationalis
Contra Cancrum tumor, node, metastasis classification.21 Pa-
tients without mediastinal and/or hilar lymph node metastases
underwent CIRT; however, those with lymph node metasta-
ses underwent other types of treatment. All patients who
received CIRT had routine follow-ups at the NIRS including
CT scan of the chest and abdomen, 11C-methionine-PET-CT,
and brain MRI. EBUS-TBNA diagnosis was confirmed either
by restaging by EBUS-TBNA or clinical follow-up.
This study was approved by the ethical committee of
Graduate School of Medicine, Chiba University (No. 825).
Endobronchial Ultrasound-Guided
Transbronchial Needle Aspiration
EBUS-TBNA was performed on an outpatient basis
under conscious sedation. Local anesthesia was achieved
using nebulized 1% lidocaine solution (5 mL) to the pharynx.
A bolus dose of 2 mL of 1% lidocaine was used during the
procedure. The bronchoscope was inserted orally with con-
scious sedation using midazolam. Patients were monitored by
electrocardiograph, pulse oximetry, and blood pressure with-
out the presence of an anesthesiologist.
Convex prove-EBUS (BF-UC260F-OL8, Olympus,
Tokyo, Japan) was used for the examination of mediastinal
and hilar lymph nodes. The convex prove-EBUS was inte-
grated with a convex transducer (7.5 MHz) that scanned
parallel to the insertion direction of the bronchoscope. Images
could be obtained by directly contacting the probe or by
attaching a balloon to the tip and inflating with saline. The
ultrasound image was processed using a dedicated ultrasound
scanner (EU-C2000, Olympus, Tokyo, Japan) and was visu-
alized along with the conventional bronchoscopy image on
the same monitor. A dedicated 22-gauge needle was used to
perform transbronchial aspiration (NA-201SX-4022, Olym-
pus, Tokyo, Japan).
After the needle is passed into the node, the internal
stylet is moved in and out a short distance to clean out the
internal lumen that may be plugged with bronchial wall. The
internal stylet is then removed. The internal stylet was re-
moved, and negative pressure was applied using a syringe.
The needle was moved back and forth inside the tumor.
Finally, the needle was retrieved, and the internal stylet was
used once again to push out the histologic core.15 Using this
method, histologic cores and cytologic specimens were ob-
tained. The aspirated material was smeared onto glass slides.
Smears were air dried and immediately stained by Diff-Quik
staining for immediate interpretation by an onsite cyto-
pathologist to confirm adequate cell material. Papanicolaou
and light microscopy were also done by an independent
cytopathologist who was blinded to the details of the cases.
The histologic cores were fixed with formalin and stained
with hematoxylin and eosin. Immunohistochemistry was used
for firm diagnosis. If there were adequate amount of lympho-
cytes without malignant cells or lymph node fragment with-
out malignant cells, this was defined as benign lymph nodes.
Carbon Ion Radiotherapy
Carbon ion beams with 290, 350, and 400 meV/nucleon
energies were generated in the Heavy Ion Medical Acceler-
ator in Chiba. To compensate for tumor thickness, therapy
was delivered by spread-out Bragg peaks.22,23 Patients were
immobilized with custom-made devices. CT planning was
performed using the HIPLAN system, which was specifically
developed for three-dimensional treatment planning with CT
images using respiratory gating. A respiratory gating irradi-
ation system was used to minimize respiratory motion of the
tumor and to reduce the treatment volume.24 The carbon ion
radiation dose was expressed in Gray equivalents (GyE). The
GyE values were calculated by multiplying the carbon phys-
ical dose (Gy) with the Relative Biologic Effectiveness fac-
tor, which was approximately 3.0.23 The patients who re-
ceived CIRT were irradiated in several protocols in the NIRS.
The irradiation ranged from a total dose of 36.0 GyE with a
regimen of 1 fraction to a total dose of 72.0 GyE with a
regimen of 16 fractions (mean radiation dose was 49.50 GyE,
3.34 fractions). Our routine follow-up for patients post-CIRT
includes clinic visits at 1, 3, 6, 9 months, thin slice CT (1–3
mm thick) every 3 months, and 11C-methionine-PET-CT and
brain MRI 1 and 3 months after treatment.
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Data Analysis
The diagnostic accuracy rate was calculated using stan-
dard definitions.
RESULTS
Patient Characteristics
One hundred twenty-five lymph nodes (86 mediastinal
and 39 hilar lymph nodes) from 49 patients with NSCLC
were evaluated by EBUS-TBNA in this study. The charac-
teristics of the 49 patients are listed in Table 1. All patients
enrolled in this study showed abnormal 11C-methionine-
PET-CT accumulations in mediastinal and/or hilar lymph
nodes. Clinical stages based on the results of 11C-methionine-
PET-CT were four cases of N1 disease, 42 cases of N2
disease, and three cases of N3 disease. The reasons for CIRT
were as follows: 31 cases had low pulmonary functions and
were determined inoperable by referring surgeons, six cases
had cardiovascular disease, four cases were of advanced age
with poor systemic conditions, and eight cases refused sur-
gery for personal reasons.
Lymph Node Evaluations
All positive lymph nodes on PET-CT were assessed
and all lymph nodes accessible by EBUS-TBNA; the mean
number of evaluated lymph nodes was 2.55 stations per
patient (range 1–5 stations per patient) (Table 2). The right
lower paratracheal lymph node (no. 4R) was most often
examined with 38 nodes, followed by 31 for subcarinal
lymph nodes (no. 7), 29 for interlobar lymph nodes (no. 11),
eight for right upper paratracheal lymph nodes (no. 2R) and
eight left lower paratracheal lymph nodes (no. 4L), seven for
lobar lymph nodes (no. 12), three for hilar lymph nodes (no.
10), and one for a retrotracheal lymph node (no. 3). Lymph
node sizes on CT varied from 5 to 19 mm in the short axis
with an average of 9.5 mm, and the sizes by endobronchial
ultrasound varied from 3.1 to 22.6 mm in the short axis with
an average of 9.01 mm (Table 2).
EBUS-TBNA Results
We did not experience any complications related to the
EBUS-TBNA procedures. Pathologic diagnosis was achieved
in all patients, and lymph node metastases were diagnosed in
six cases (12.2%), which included four cases of adenocarci-
noma and two cases of squamous cell carcinoma. The posi-
tive cases were all N2 disease, and the metastatic sites were
four cases of the subcarinal lymph node (no. 7) and two cases
of the right lower paratracheal lymph node (no. 4R). In the
metastatic cases, the average lymph node size in the short
axis was 10.5 mm on CT (5–15 mm) and 10.9 mm on EBUS
(3.7–17.7 mm) (Table 3). The cases with lymph node metas-
tases were referred for other treatment modalities. The other
43 of 49 cases who showed no lymph node metastases by
EBUS-TBNA finally received CIRT.
TABLE 1. Patient Characteristics
Age (yr)
Average 75.2
Range 55–87
Sex (n  49)
Male 38
Histology
Adenocarcinoma 26
Squamous cell carcinoma 19
Large cell carcinoma 1
Non-small cell lung cancer 3
PET-CT N stage
N1 disease 4
N2 disease 42
N3 disease 3
Reason for CIRT
Low pulmonary function 31
Cardiovascular disease 6
Other disease 4
Refused surgery 8
PET-CT, positron emission tomography-computed tomography; CIRT, carbon ion
radiotherapy.
TABLE 2. Lymph Node Stations Punctured by EBUS-TBNA
Mean (Range)
CT (Size/mm) EBUS (Size/mm)
Station
No. 2R (n  8) 6.9 (5–12) 7.2 (5.0–10.6)
No. 3 (n  1) 16.0 10.6
No. 4R (n  38) 9.3 (5–19) 7.8 (3.7–22.6)
No. 4L (n  8) 9.5 (5–15) 8.5 (4.5–12.1)
No. 7 (n  31) 9.0 (5–15) 10.8 (3.1–19.2)
No. 10 (n  3) 7.7 (5–12) 10.7 (9.0–12.8)
No. 11 (n  29) 8.8 (5–15) 8.2 (4.5–12.4)
No. 12 (n  7) 8.9 (5–12) 8.3 (5.0–14.0)
Region
Mediastinum (n  86)
Hilar or Lobar (n  39)
Total (n  125) 9.5 (5–19) 9.0 (3.1–22.6)
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration;
CT, computed tomography.
TABLE 3. Lymph Node Sizes and Likelihood of Metastasis
Negative for
Metastasis Short
Axis in mm (Range)
Positive for
Metastasis Short
Axis in mm (Range)
Station (metastatic rate)
CT
No. 4R (2/38; 5.3%) 9.4 (5–19) 7.5 (5–10)
No. 7 (4/31; 12.9%) 8.6 (5–15) 12.0 (10–15)
EBUS
No. 4R (2/38; 5.3%) 7.8 (4.2–22.6) 6.9 (3.7–10.1)
No. 7 (4/31; 12.9%) 10.5 (3.1–19.2) 13.0 (9.2–17.7)
Average
CT 9.0 (5–19) 10.5 (5–11)
EBUS 9.0 (3.1–22.6) 10.9 (3.7–17.7)
EBUS-TBNA, endobronchial ultrasound guided; CT, computed tomography.
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The results from EBUS-TBNA were confirmed either
by restaging by EBUS-TBNA or by clinical follow-up (me-
dian 21.3 months, range 6–46 months). Three of 43 cases had
detected interlobar lymph node metastases (no. 11) after
CIRT and were judged as false-negative cases. Two of these
three cases revealed metastases by EBUS-TBNA, and one
case showed lymph node enlargement and multiple pulmo-
nary metastases with abnormal accumulation on 11C-methi-
onine-PET-CT. The median period for detecting lymph node
metastasis was 4.33 months after CIRT (range 4–5 months).
One of the three cases had metastasis in previously aspirated
lymph nodes before CIRT. The other two cases showed
lymph node metastases in lymph nodes previously not eval-
uated by EBUS-TBNA. The diagnostic accuracy of EBUS-
TBNA for diagnosis of mediastinal and hilar lymph node
metastasis was 93.9% (Table 4).
DISCUSSION
Our report is the first to evaluate EBUS-TBNA for
mediastinal and hilar lymph node staging in patients with
NSCLC in nonoperable patients pursuing radiotherapy as a
primary treatment. Lymph node staging modalities for pa-
tients who are referred for CIRT are limited, because these
selected groups of individuals are likely to have multiple
comorbidities and surgical interventions should be avoided.
EBUS-TBNA is a novel, minimally invasive modality with a
high yield for lymph node staging in lung cancer that can be
performed under local anesthesia in an outpatient setting.14–19
The diagnostic accuracy for lymph node staging in this
study was very high (93.9%), similar to previous reports on
lung cancer staging.14–19 It was also a safe procedure, even
for a relatively high risk population, because we did not
encounter any complications related to EBUS-TBNA. Re-
garding the sizes of lymph nodes, the minimum size of a
positive node was 5 mm on CT and 3.7 mm on EBUS (Figure
1). Nevertheless, there were numerous negative lymph nodes
1 cm in the short axis on CT. The maximum size of a
negative node was 19 mm on CT and 22.6 mm on EBUS
(Figure 2). From these results, tissue confirmation should
always be considered during mediastinal staging. We believe
that EBUS-TBNA may also be applicable as a highly precise
pretreatment staging modality for various other radical radio-
therapy treatments.
Although chest CT has been used for the staging of lung
cancer for a long time, its low diagnostic accuracy is a signifi-
cant problem. New diagnostic modalities, such as PET and
integrated PET-CT, have been reported to be useful for the
detection of mediastinal and hilar lymph node metastases in
patients with NSCLC.25–27 Nevertheless, there are limitations for
imaging modalities due to the lack of pathologic confirmation.
Surgical candidates such as mediastinoscopy12,13 requires
general anesthesia and should be avoided in high risk
patients with contraindications for surgical interventions.
Furthermore, hilar lymph nodes cannot be evaluated by
FIGURE 1. Chest computed to-
mography (CT), positron emission
tomography (PET)-CT, endobron-
chial ultrasound-guided (EBUS) im-
ages, and cytology in a patient
with clinical N0 non-small cell lung
cancer. Although the size of the
lymph node was 5 mm in the
short axis (A), 11C-methionine-
PET-CT showed abnormal accumu-
lation in the no. 4R lymph node
(B). EBUS-TBNA from lymph node
station 4R (no. 4R) with short axis
of 3.7 mm (C) revealed adenocarci-
noma (D) and therefore diagnosed
as N2 disease.
TABLE 4. Comparison of EBUS-TBNA Results of Lymph
Nodes with Final Diagnosis
Final Results
EBUS-TBNA Results
Malignant Benign Total
Malignant 6 3a 9
Benign 0 40 40
Total 6 43 49
aTwo metastatic cases were detected in unevaluated lymph node.
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration.
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mediastinoscopy, and N1 stations (hilar lymph nodes)
should also be evaluated before CIRT.
11C-methionine-PET-CT has been used for assessment
of potential candidates for CIRT.20 It is reported that 11C-
methionine-PET-CT could be used to evaluate the treatment
effect of SRT and 18F-fluorodeoxy glucose (FDG)-PET-CT.28
In this study, abnormal accumulations in mediastinal and/or
hilar lymph nodes on 11C-methionine-PET-CT were evalu-
ated. As reported previously, the negative predictive value of
FDG-PET for mediastinal staging is high, and we rarely see
patients with nodal disease when both CT and FDG-PET
scans are negative.16 On the other hand, false-positive results
on FDG-PET scans are frequently seen in patients with lung
cancer with pulmonary complications, and positive results
should be carefully evaluated.29 In our study population, 31
patients (63.3%) had similar low pulmonary function because
of several pulmonary complications such as chronic obstruc-
tive pulmonary diseases. Previous reports suggest possibili-
ties of abnormal accumulation on PET scan, which may lead
to false positives in chronic inflammatory lesions.29 Although
11C-methionine-PET-CT has been shown to be more specific
and sensitive compared with 18F-FDG-PET for differentiat-
ing benign and malignant thoracic nodules/masses,30 the
results of our study do not support this. Surprisingly, only 9
of 49 cases (18.4%) with positive lymph nodes on 11C-
methionine-PET-CT were proven to have metastases by
EBUS-TBNA. We can conclude that PET-positive cases are
recommended for further pathologic confirmations using a
proper modality such as EBUS-TBNA. On the other hand, it
has been reported that the negative predictive value of
PET-CT is high (11C-methionine-PET-CT for 94.1%),16,20
and it is useful to determine the indication for further invasive
staging modality such as EBUS-TBNA.
CIRT is a promising modality with excellent localiza-
tion and significant biologic effects on tumors. It is feasible
for patients with stage I NSCLC without severe loss of
respiratory functions.31 In contrast to SRT and proton beam
radiotherapy, which show good local control rate in T1
tumors, CIRT has been shown to be effective even in T2
tumors with a local control rate of more than 85%.6–10 CIRT
can be safely performed in elderly patients older than 80
years and was effective in treating elderly patients with stage
I NSCLC.5–11 The need for CIRT is increasing in an aging
society, and various other irradiations have been attempted,
such as proton therapy and stereotactic irradiation. Neverthe-
less, the success depends primarily on accurate staging before
radiotherapy. Accurate lymph node staging by EBUS-TBNA
will allow opportunities for high-risk inoperable patients with
NSCLC to undergo minimally invasive treatment.
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